Philip C Spinella

Philip C. Spinella, MD

  • Pediatric Critical Care

Sees Patients For

pediatric intensive care,

Patients Seen At

Hospital Affiliations

  • St. Louis Children's Hospital

Board Certifications

  • Pediatrics
  • Pediatric Critical Care

Academic Title(s)

Professor, Pediatrics
Division of Critical Care Medicine

Languages

  • English

Education

Residency

1998 Pediatrics, Tripler Army Medical Centern Honolulu, Hawaii

BS (Biology)

1991 Tufts University, Medford, MA,

Medical Degree

1996 New York Medical College, Valhalla, NY

Fellowship

2003 Pediatric Critical Care Medicine, Children's Hospital of Pennsylvania

Research Interests

Dr. Spinella’s research program focuses on examining the biologic consequences of blood product manufacturing by both exploring mechanisms in the lab and performing clinical trials to determine clinical relevance. The laboratory has developed a unique microfluidic assay of hemostasis that simulates bleeding. This assay is primary used to characterize the coagulopathy associated with multiple etiologies and the hemostatic response of different blood products according to the etiology or mechanisms of coagulopathy. The laboratory is also currently focused on mechanisms associated with the platelet storage lesion and how platelet storage temperature affects it. Dr. Spinella is also leading an international randomized controlled trial to examine the efficacy and safety of cold stored platelets compared to room temperature platelets for complex cardiac surgery patients with active bleeding. He is a co-founder of Kalocyte, which is developing a freeze dried artificial red cell and working with other industries to examine the efficacy and safety of dried plasma, improved RBC storage solutions, and nanoparticle based hemostatic agents that facilitate platelet adhesion and aggregation. Dr. Spinella has also established transfusion and hemostasis focused research networks to include the Pediatric Critical Care Blood Research Network and the Trauma Hemostasis and Oxygenation Research (THOR) Network.

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

Company Name: EntegrionRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $100,000 - $149,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2020
Company Name: KaloCyteRoyalties: $1 - $9,999Equity: YesConsulting/Advisory Board: $1 - $9,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2020
Company Name: New Health SciencesRoyalties: $1 - $9,999Equity: NoConsulting/Advisory Board: $60,000 - $79,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2020
Company Name: Secure Transfusion ServicesRoyalties: $1 - $9,999Equity: YesConsulting/Advisory Board: $80,000 - $99,999Speaker Fees: $1 - $9,999Reporting Date: 05/01/2020